Drugs / Quadrivalent High-dose Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05071313 | Oct 2021 → Apr 2022 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent High-dose Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05071313 ↗ |
| Modality | Vaccine | “Quadrivalent High-dose Influenza Vaccine” NCT05071313 ↗ |
| Route | Intramuscular | “administered as IM injection” NCT05071313 ↗ |